Elyes

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT ELYES (ELYES)

Composition:

Active substance: apixaban;

One film-coated tablet contains 5 mg of apixaban;

Excipients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose, sodium lauryl sulfate, magnesium stearate; film coating: Opadry II Pink (32K540099) (hypromellose 15 mPaS / HPMC 2910; lactose monohydrate; titanium dioxide (E 171); triacetin; iron oxide red (E 172)).

Pharmaceutical form. Film-coated tablets.

Main physicochemical properties: pink, oval, biconvex, film-coated tablets, embossed with "I2" on one side and smooth on the other.

Pharmacotherapeutic group. Antithrombotic agents. Direct factor Xa inhibitors. ATC code B01AF02.

Pharmacological Properties

Pharmacodynamics

Mechanism of Action

Apixaban is a potent, reversible, direct, and highly selective inhibitor of the active site of factor Xa, intended for oral administration. It does not require antithrombin III for its antithrombotic activity. Apixaban inhibits both free and clot-bound factor Xa, as well as prothrombinase activity. Apixaban does not directly affect platelet aggregation, but indirectly inhibits thrombin-induced platelet aggregation. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus formation. Preclinical studies of apixaban in animals demonstrated effective antithrombotic activity in the prevention of arterial and venous thrombosis at doses that did not impair hemostatic processes.

Pharmacodynamic Effects

The pharmacodynamics of apixaban reflect its mechanism of action (inhibition of factor Xa). As a result of factor Xa inhibition, apixaban increases the values of prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT). Changes in coagulation parameters observed during therapeutic dosing are minimal and highly variable, and are not recommended for assessing the pharmacodynamic effects of apixaban. In thrombin generation assays, apixaban reduced endogenous thrombin potential, a marker of thrombin formation in human plasma.

Apixaban also demonstrates activity against factor Xa, as evidenced by reduced enzymatic activity of factor Xa measured using various commercial factor Xa activity assay kits; however, results varied between different assay kits. Clinical study data are available only for the chromogenic assay Rotachrom® Heparin. Anti-Xa activity is closely and linearly correlated with apixaban plasma concentration, reaching maximum levels at peak apixaban plasma concentrations. The relationship between apixaban plasma concentration and anti-Xa activity is approximately linear over a wide range of apixaban doses.

Table 1 (see below) shows the predicted steady-state concentrations and anti-Xa activity levels for each indication. In patients with nonvalvular atrial fibrillation receiving apixaban for stroke and systemic embolism prevention, observed peak-to-trough fluctuations were less than 1.7-fold. In patients receiving apixaban for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), or for prevention of recurrent DVT and PE, peak-to-trough fluctuations were less than 2.2-fold.

Table 1

Predicted steady-state concentrations of apixaban and

anti-factor Xa activity

* Dose adjustment for the population was based on meeting 2 out of 3 dose reduction criteria in the ARISTOTLE study.

Although apixaban treatment does not require routine monitoring of exposure levels, in exceptional circumstances when information on apixaban exposure levels may assist in making a clinical decision (e.g., in cases of overdose or emergency surgery), a calibrated quantitative method for measuring anti-factor Xa activity can be used.

Clinical efficacy and safety

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation

In the clinical trial program (ARISTOTLE study: apixaban compared with warfarin, and AVERROES study: apixaban compared with acetylsalicylic acid), a total of 23,799 patients were randomized, of whom 11,927 were assigned to apixaban treatment groups. The program was designed to demonstrate the efficacy and safety of apixaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor, namely:

• prior history of stroke or transient ischemic attack;
• age ≥ 75 years;
• arterial hypertension;
• diabetes mellitus;
• symptomatic heart failure (NYHA class ≥ II).

ARISTOTLE study

In the ARISTOTLE study, a total of 18,201 patients were randomized; participants were assigned to double-blind treatment with either apixaban 5 mg twice daily (or 2.5 mg twice daily in certain patients (4.7%), see section "Posology and method of administration"), or warfarin (target INR range 2.0–3.0). Patients received study medication for a median duration of 20 months. The mean age of participants was 69.1 years, and the mean CHADS2 score was 2.1. A history of stroke or transient ischemic attack was present in 18.9% of patients.

In this study, apixaban treatment demonstrated statistically significant superiority over warfarin for the primary efficacy outcome of prevention of stroke (hemorrhagic or ischemic) and systemic embolism (see Table 2).

Table 2

Efficacy in patients with atrial fibrillation enrolled in the ARISTOTLE study

In patients assigned to warfarin treatment, the median time (%) during which the INR was within the range of 2.0–3.0 while on study drug in the therapeutic window was 66%.

Apixaban demonstrated a reduction in the rate of stroke and systemic embolism (compared to warfarin treatment) across various levels of time in the therapeutic range. For the highest quartile relative to the mean, the hazard ratio for apixaban versus warfarin was 0.73 (95% CI 0.38, 1.40).

The key secondary endpoints of major bleeding and all-cause mortality were evaluated using a pre-specified hierarchical hypothesis testing strategy to control the overall type I error rate in the study. Statistically significant benefits were also observed for the key secondary endpoints of major bleeding and all-cause mortality (see Table 3). However, with more stringent INR control, the advantages of apixaban over warfarin with respect to all-cause mortality diminished.

Table 3

Secondary endpoints in patients with atrial fibrillation in the ARISTOTLE study

* Major bleeding, defined according to criteria of the International Society on Thrombosis and Haemostasis (ISTH).

† Clinically relevant non-major.

The cumulative incidence of discontinuation due to adverse reactions in the ARISTOTLE study was 1.8% with apixaban and 2.6% with warfarin.

Efficacy results in predefined subgroups (including subgroups based on CHADS2 score, age, body weight, sex, renal function, history of stroke or transient ischemic attack, and diabetes) were consistent with the primary efficacy outcomes in the overall study population.

The rate of ISTH-classified major gastrointestinal bleeding (including upper, lower gastrointestinal tract, and rectal bleeding) was 0.76% per year with apixaban and 0.86% per year with warfarin.

Rates of major bleeding in predefined subgroups (including subgroups based on CHADS2 score, age, body weight, sex, renal function, history of stroke or transient ischemic attack, and diabetes) were consistent with results in the overall population.

AVERROES study

Overall, 5598 patients were randomized in the AVERROES study, in whom vitamin K antagonist therapy was considered unsuitable. Study participants were assigned to receive apixaban 5 mg twice daily (or 2.5 mg twice daily in some patients (6.4%) (see section "Posology and method of administration")) or acetylsalicylic acid. Acetylsalicylic acid was administered once daily at a dose of 81 mg (64%), 162 mg (26.9%), 243 mg (2.1%), or 324 mg (6.6%). The dose was determined by the investigator. Patients received the active treatment for a median duration of 14 months. The mean age of participants was 69.9 years, and the mean CHADS2 score was 2.0. 13.6% of patients had a prior history of stroke or transient ischemic attack.

Common reasons for considering vitamin K antagonist therapy unsuitable included: inability/low likelihood of achieving required international normalized ratio (INR) levels within the required timeframe (42.6%), patient refusal of vitamin K antagonist therapy (37.4%), CHADS2 score = 1 and physician recommendation against vitamin K antagonist therapy (21.3%), inability to ensure patient compliance with vitamin K antagonist dosing instructions (15%), and difficulty/potential difficulty in contacting the patient promptly when immediate dose adjustment was needed (11.7%).

The AVERROES study was terminated prematurely upon recommendation of the independent Data Monitoring Committee due to compelling evidence of reduced incidence of stroke and systemic embolism combined with a favorable safety profile of the study drug.

The cumulative incidence of discontinuation due to adverse reactions in the AVERROES study was 1.5% with apixaban and 1.3% with acetylsalicylic acid.

In this study, apixaban treatment demonstrated statistically significant benefit over acetylsalicylic acid for the primary efficacy endpoint of prevention of stroke (hemorrhagic, ischemic, or undetermined) or systemic embolism (see Table 4).

Table 4

Key efficacy outcomes in patients with atrial fibrillation in the AVERROES study

* Assessment using a sequential testing strategy designed to control the overall type I error rate in the study.

† Secondary endpoint.

There was no statistically significant difference in the rate of major bleeding between apixaban and acetylsalicylic acid (see Table 5).

Table 5

Bleeding events in patients with atrial fibrillation in the AVERROES study

* Major bleeding defined according to criteria of the International Society on Thrombosis and Haemostasis (ISTH).

† Clinically relevant non-major.

Patients with non-valvular atrial fibrillation (NVAF) and acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI)

In the AUGUSTUS trial — an open-label, randomized, controlled 2-by-2 factorial design study — 4,614 patients with NVAF who had ACS (43%) and/or underwent PCI (56%) were enrolled. All patients received background therapy with a P2Y12 inhibitor (clopidogrel: 90.3%), administered according to local treatment standards.

Patients within 14 days after ACS and/or PCI were randomized to receive apixaban 5 mg twice daily (2.5 mg twice daily if patients met two or more dose-reduction criteria; 4.2% received the lower dose) or a vitamin K antagonist (VKA) and aspirin (ASA) (81 mg once daily) or placebo. The mean age of patients was 69.9 years, 94% of randomized patients had a CHA2DS2-VASc score >2, and 47% had a HAS-BLED score >3. For patients randomized to VKA, the time in the therapeutic range (TTR) (INR 2–3) was 56%, with 32% of time below and 12% above the therapeutic range.

The primary objective of the AUGUSTUS trial was to assess safety, with the primary endpoint being major or clinically relevant non-major bleeding according to ISTH criteria. In the apixaban versus VKA comparison group, the primary endpoint — major or clinically relevant non-major bleeding according to ISTH criteria at 6 months — occurred in 241 (10.5%) and 332 (14.7%) patients in the apixaban and VKA groups, respectively (HR = 0.69, 95% CI: 0.58, 0.82; two-sided p<0.0001 for non-inferiority and p<0.0001 for superiority). A supplementary analysis for VKA using TTR subgroups showed that the highest bleeding rate was associated with the lowest TTR quartile. The bleeding rate was similar when comparing apixaban with VKA in the highest TTR quartile subgroup.

In the comparison of ASA versus placebo, the primary endpoint — major or non-major clinically relevant bleeding according to ISTH criteria at 6 months — occurred in 367 (16.1%) and 204 (9.0%) patients in the ASA and placebo groups, respectively (HR = 1.88, 95% CI: 1.58, 2.23; two-sided p<0.0001).

Specifically, in patients receiving apixaban treatment, major or clinically relevant non-major bleeding occurred in 157 (13.7%) and 84 (7.4%) patients in the ASA and placebo groups, respectively. In patients receiving VKA treatment, major or clinically relevant non-major bleeding occurred in 208 (18.5%) and 122 (10.8%) patients in the ASA and placebo groups, respectively.

Other treatment effects were evaluated as secondary trial objectives using composite endpoints.

In the apixaban versus VKA comparison, the composite endpoint of death or recurrent hospitalization occurred in 541 (23.5%) and 632 (27.4%) patients in the apixaban and VKA groups, respectively. The composite endpoint of death or ischemic event (stroke, myocardial infarction, stent thrombosis, or urgent revascularization) occurred in 170 (7.4%) and 182 (7.9%) patients in the apixaban and VKA groups, respectively.

In the ASA versus placebo comparison, the composite endpoint of death or recurrent hospitalization occurred in 604 (26.2%) and 569 (24.7%) patients in the ASA and placebo groups, respectively. The composite endpoint of death or ischemic event (stroke, myocardial infarction, stent thrombosis, or urgent revascularization) occurred in 163 (7.1%) and 189 (8.2%) patients in the ASA and placebo groups, respectively.

Patients undergoing cardioversion

EMANATE — an open-label, multicenter trial involving 1,500 patients who were not receiving oral anticoagulants or had received prior therapy for less than 48 hours and were scheduled for cardioversion for NVAF.

Patients were randomized in a 1:1 ratio to receive either apixaban or heparin and/or vitamin K antagonists for prevention of cardiovascular events. Electrical and/or pharmacological cardioversion was performed after at least 5 doses of apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients), or at least 2 hours after a 10 mg loading dose (or 5 mg loading dose in selected patients) if early cardioversion was required (see section "Dosage and administration"). In the apixaban treatment group, 342 patients received a loading dose (331 patients received a 10 mg dose, and 11 received a 5 mg dose).

In the apixaban treatment group (n = 753), there were no strokes (0%), compared to 6 (0.80%) strokes in the heparin and/or vitamin K antagonist group (n = 747; OR 0.00, 95% CI: 0.00, 0.64). All-cause mortality occurred in 2 patients (0.27%) in the apixaban group and in 1 patient (0.13%) in the heparin and/or vitamin K antagonist group. No cases of systemic embolism were reported.

Major and clinically relevant non-major bleeding events occurred in 3 (0.41%) and 11 (1.50%) patients, respectively, in the apixaban group, compared to 6 (0.83%) and 13 (1.80%) patients in the heparin and/or vitamin K antagonist group.

The exploratory study demonstrated comparable efficacy and safety between the apixaban and heparin and/or vitamin K antagonist treatment groups during cardioversion.

Treatment of DVT, treatment of PE, and prevention of DVT and PE recurrence (VTE).

The clinical program (AMPLIFY: apixaban vs. enoxaparin/warfarin; AMPLIFY-EXT: apixaban vs. placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY) and the extended potential of the drug in preventing recurrence of DVT and/or PE after 6–12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT). Both studies were randomized, double-blind, international, parallel-group trials conducted in patients with symptomatic proximal DVT or symptomatic PE. All primary efficacy and safety endpoints were assessed by an independent committee based on blinded data.

AMPLIFY study

In the AMPLIFY study, 5,395 patients were randomized to receive either apixaban 10 mg orally twice daily for 7 days, followed by apixaban 5 mg orally twice daily for 6 months, or enoxaparin 1 mg/kg subcutaneously twice daily for at least 5 days (until INR ≥2) and warfarin (target INR range 2.0–3.0) orally for 6 months.

The mean patient age was 56.9 years, and 89.8% of randomized patients had unprovoked VTE events.

In patients assigned to the warfarin treatment group, the mean percentage of time in the therapeutic INR range (2.0–3.0) was 60.9%. Apixaban demonstrated a reduced rate of recurrent symptomatic VTE or VTE-related death across various levels of mean time in the therapeutic INR window. For the highest quartile relative to the mean, the risk ratio for apixaban versus enoxaparin/warfarin was 0.79 (95% CI: 0.39, 1.61).

This study demonstrated that apixaban was non-inferior to enoxaparin/warfarin for the primary composite efficacy endpoint of recurrent symptomatic VTE (DVT or PE without fatal outcome) or VTE-related death (see Table 6).

Table 6

Efficacy results from the AMPLIFY study

• Non-inferior efficacy compared to enoxaparin/warfarin (p-value <0.0001)

The efficacy of apixaban during initial treatment of VTE was comparable in patients receiving the drug for the treatment of PE [relative risk 0.9; 95% CI (0.5, 1.6)] or DVT [relative risk 0.8; 95% CI (0.5, 1.3)]. Efficacy across subgroups, including those classified by age, sex, body mass index (BMI), renal function, PE severity score, location of DVT thrombus, and prior use of parenteral heparin, was generally consistent.

The primary safety endpoint was major bleeding. In this study, apixaban demonstrated statistically significant advantages compared to enoxaparin/warfarin for the primary safety endpoint [relative risk 0.31, 95% CI (0.17, 0.55), p-value <0.0001] (see Table 7).

Table 7

Bleeding outcomes from the AMPLIFY study

Significant bleeding and clinically relevant non-major bleeding (CRNMB) at any anatomical site were generally lower in the apixaban group compared to the enoxaparin/warfarin group. ISTH-defined major gastrointestinal bleeding occurred in 6 patients (0.2%) receiving apixaban and in 17 patients (0.6%) receiving enoxaparin/warfarin.

AMPLIFY-EXT study

In the AMPLIFY-EXT study, 2482 patients were randomized to receive either apixaban 2.5 mg orally twice daily, apixaban 5 mg orally twice daily, or placebo for 12 months following completion of an initial course of anticoagulant therapy lasting 6–12 months. Of these,

836 patients (33.7%) had participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study.

The mean patient age was 56.7 years, and 91.7% of randomized patients had unprovoked VTE events.

In this study, both apixaban doses demonstrated statistically significant benefits compared to placebo for the primary efficacy outcome of symptomatic recurrent VTE (DVT or non-fatal PE) or death from any cause (see Table 8).

Table 8

Efficacy outcomes in the AMPLIFY-EXT study

¥ p <0.0001.

* For patients who experienced more than one event comprising the composite primary endpoint, only the first event was reported (e.g., if a study participant experienced DVT first, followed by PE, only the DVD was reported).

† Individual patients may have experienced more than one event, and events may have been counted in both categories.

The efficacy of apixaban for the prevention of recurrent VTE remained consistent across various subgroups, including those classified by age, sex, body mass index, and renal function.

The primary safety endpoint was major bleeding during the treatment period. In this study, the rate of major bleeding for both apixaban doses was not statistically different from placebo. There was no statistically significant difference in the rates of major, clinically relevant, non-major (CRNM), and all bleeding events between the apixaban 2.5 mg twice daily and placebo groups (see Table 9).

Table 9

Bleeding outcomes in the AMPLIFY-EXT study

According to ISTH assessment, major gastrointestinal bleeding occurred in 1 (0.1%) patient receiving apixaban 5 mg twice daily, in none of the patients receiving the dose of

2.5 mg twice daily, and in 1 (0.1%) patient receiving placebo.

Paediatric population

There are no approved indications for the use of the medicinal product in children (see section "Posology and method of administration").

Prevention of VTE in children with acute lymphoblastic leukaemia or lymphoblastic lymphoma (ALL, LBL)

The PREVAPIX-ALL study included 512 patients aged ≥1 to <18 years with newly diagnosed ALL or LBL who were undergoing induction chemotherapy including asparaginase, and who had a central venous access device, randomized 1:1 to open-label thromboprophylaxis with apixaban or standard of care (without systemic anticoagulants). Apixaban was administered according to a body weight-based fixed-dose regimen designed to achieve exposure comparable to that observed in adults receiving 2.5 mg twice daily (see Table 10). Apixaban was given as 2.5 mg tablets, 0.5 mg tablets, or 0.4 mg/mL oral solution. The mean duration of apixaban exposure in the group of patients who received it was 25 days.

Table 10

Apixaban dosing in the PREVAPIX-ALL study

The primary efficacy endpoint was the composite of confirmed symptomatic and asymptomatic non-fatal deep vein thrombosis, pulmonary embolism, cerebral venous sinus thrombosis, and death related to venous thromboembolism. The incidence of the primary efficacy endpoint was 31 (12.1%) in the apixaban group compared to 45 (17.6%) in the standard therapy group. The relative risk reduction did not reach statistical significance.

Safety endpoints were assessed according to ISTH criteria. The major safety endpoint, major bleeding, occurred in 0.8% of patients in each treatment group. Clinically relevant non-major (CRNM) bleeding occurred in 11 patients (4.3%) in the apixaban group and in 3 patients (1.2%) in the standard therapy group. The most common CRNM bleeding events accounting for the treatment difference were mild to moderate epistaxis. Minor bleeding occurred in 37 patients (14.5%) in the apixaban group and in 20 patients (7.8%) in the standard therapy group.

Prevention of thromboembolism (TE) in children with congenital or acquired heart disease SAXOPHONE is a randomized, open-label, multicenter, comparative 2:1 study involving patients under 18 years of age with congenital or acquired heart disease requiring anticoagulation. Patients received either apixaban or standard thromboprophylaxis with vitamin K antagonist or low molecular weight heparin. Apixaban was administered according to a body weight-based fixed-dose regimen designed to achieve exposure comparable to that observed in adults receiving 5 mg twice daily (see Table 11). Apixaban was given as 5 mg tablets, 0.5 mg tablets, or 0.4 mg/mL oral solution. The mean duration of apixaban exposure in the treated patient group was 331 days.

Table 11

Apixaban dosing in the SAXOPHONE study

The primary safety endpoint, a composite of ISTH-defined major and clinically relevant non-major (CRNM) bleeding, occurred in 1 (0.8%) of 126 patients receiving apixaban and in 3 (4.8%) of 62 patients receiving standard therapy. The definition of the secondary safety endpoint (major bleeding, CRNM bleeding, and all bleeding events) was discontinued due to adverse reactions, intolerance, or bleeding, reported in 7 (5.6%) patients in the apixaban group and 1 (1.6%) patient in the standard therapy group. No thromboembolic events were observed in any patient in either treatment group. There were no fatal outcomes in either treatment group.

This study was prospectively designed for descriptive efficacy and safety due to the expected low frequency of thromboembolic (TE) events and bleeding in this population. Due to the observed low frequency of TE events, a definitive assessment of risk and benefit could not be performed in this study.

The European Medicines Agency has deferred the obligation to submit the results of studies with apixaban involving pediatric patients belonging to one or more subgroups (information on pediatric use can be found in section "Posology and method of administration").

Pharmacokinetics.

Absorption

The absolute bioavailability of apixaban following doses up to and including 10 mg is approximately 50%. Apixaban is rapidly absorbed, with peak drug concentration (Cmax) reached within 3–4 hours after tablet intake. Food intake does not affect the AUC or Cmax of apixaban when a 10 mg dose is administered. Apixaban can be taken independently of food intake.

Following oral administration at doses not exceeding 10 mg, the pharmacokinetics of apixaban demonstrate a linear profile with dose-proportional increases in exposure. At doses ≥ 25 mg, apixaban exhibits solubility-limited absorption with reduced bioavailability. Apixaban exposure parameters show low to moderate variability, reflected by an intra-participant variability of approximately 20% coefficient of variation (CV) and inter-participant variability of approximately 30% CV.

Following oral administration of 10 mg apixaban as 2 crushed 5 mg tablets suspended in 30 mL of water, exposure was comparable to that observed after oral administration of 2 intact 5 mg tablets. Following oral administration of 10 mg apixaban as 2 crushed 5 mg tablets mixed with 30 g of apple puree, Cmax and AUC values were 21% and 16% lower, respectively, compared to administration of 2 intact 5 mg tablets.

This reduction in exposure is not considered clinically significant.

Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of 5% glucose solution and administered via nasogastric tube, exposure was similar to that observed in other clinical studies in healthy volunteers who received a single 5 mg apixaban tablet orally.

Given the predictable dose-proportional pharmacokinetic profile of apixaban, the results of bioavailability studies are applicable to lower doses of apixaban.

Distribution

Plasma protein binding in humans is approximately 87%. The volume of distribution is approximately 21 liters.

Biotransformation and elimination

Apixaban is eliminated from the body via multiple pathways. Approximately 25% of the administered dose of apixaban is excreted as metabolites, with the majority of metabolites eliminated in feces. Renal clearance of apixaban accounts for approximately 27% of total clearance. Additional roles of biliary and direct intestinal excretion pathways were observed in clinical and preclinical studies.

The total clearance of apixaban is approximately 3.3 L/h, and the elimination half-life is approximately 12 hours.

The main biotransformation pathways are O-demethylation and hydroxylation of the 3-oxopiperidinyl core. Apixaban metabolism is primarily mediated by CYP3A4/5. CYP1A2, 2C8, 2C9, 2C19, and 2J2 play minor roles in drug metabolism. In human plasma, unchanged apixaban is the predominant circulating compound associated with this medicinal product. There are no active circulating metabolites of apixaban in plasma. Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP).

Elderly patients

Higher plasma concentrations of apixaban were observed in elderly patients (over 65 years of age) compared to younger patients; mean AUC values in elderly patients were approximately 32% higher, with no change in Cmax.

Renal impairment

Renal function impairment did not affect the peak concentration of apixaban. Based on creatinine clearance assessments, increased apixaban exposure correlated with decreased renal function. In individuals with mild (creatinine clearance 51–80 mL/min), moderate (creatinine clearance 30–50 mL/min), and severe (creatinine clearance 15–29 mL/min) renal impairment, plasma concentrations of apixaban increased by 16%, 29%, and 44%, respectively, compared to individuals with normal creatinine clearance. Renal impairment did not have a pronounced effect on the relationship between apixaban plasma concentration and the degree of factor Xa inhibition.

In patients with end-stage renal disease (ESRD), apixaban AUC increased by 36% when a single 5 mg dose of apixaban was administered immediately after hemodialysis, compared to patients with normal renal function. Hemodialysis initiated two hours after administration of a single 5 mg dose of apixaban reduced apixaban AUC by 14% in these ESRD patients, corresponding to a dialysis clearance of apixaban of 18 mL/min. Thus, hemodialysis is unlikely to be an effective treatment for apixaban overdose.

Hepatic impairment

In a study where 8 participants with mild hepatic impairment (Child-Pugh class A with score 5 (n=6) and 6 (n=2)) and 8 participants with moderate hepatic impairment (Child-Pugh class B with score 7 (n=6) and 8 (n=2)) were compared with 16 healthy control volunteers, the pharmacokinetics and pharmacodynamics of a single 5 mg dose of apixaban were not altered by hepatic impairment. Changes in factor Xa inhibition activity and international normalized ratio were comparable between healthy volunteers and patients with mild or moderate hepatic impairment.

Sex

Apixaban exposure levels in women were approximately 18% higher than in men.

Ethnic origin and race

Phase I study results indicate no notable differences in apixaban pharmacokinetic parameters between Caucasian, Mongoloid, and Negroid populations. Population pharmacokinetic analysis results in patients receiving apixaban were consistent with Phase I study findings.

Body weight

Compared to apixaban exposure in individuals with body weight between 65 and 85 kg, exposure was reduced by approximately 30% in individuals with body weight above 120 kg, and increased by approximately 30% in individuals with body weight below 50 kg.

Pharmacodynamic / pharmacokinetic relationship

The pharmacokinetic/pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and certain PD endpoints (factor Xa inhibition activity, PT, aPTT, and TT) was evaluated after administration of various apixaban doses across a wide range from 0.5 to 50 mg. The relationship between apixaban plasma concentration and factor Xa inhibition activity was best described by a linear model. PK/PD relationships observed in patients were consistent with those in healthy volunteers.

Preclinical safety data

Preclinical studies revealed no special hazard for humans based on conventional investigations of pharmacological safety, repeated-dose toxicity, genotoxicity, carcinogenic potential, fertility, and embryofetal development, or juvenile toxicity.

The main effects observed in repeated-dose toxicity studies were related to the pharmacodynamic action of apixaban on coagulation parameters. No significant increase in bleeding tendency was observed during toxicity studies. However, since this may be due to lower species sensitivity in preclinical studies compared to humans, this result should be interpreted with caution when extrapolating to humans.

In rat milk, a high milk-to-plasma ratio (Cmax ratio about 8, AUC ratio about 30) was observed, possibly due to active transport into milk.

Clinical characteristics.

Indications.

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors such as prior history of stroke or transient ischemic attack (TIA), age ≥ 75 years, hypertension, diabetes mellitus, or symptomatic heart failure (NYHA class ≥ II).

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prevention of recurrent DVT and PE in adults (information regarding patients with PE and unstable hemodynamics is provided in the section "Special precautions").

Contraindications.

Hypersensitivity to the active substance or to any of the excipients.

Clinically significant active bleeding.

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section "Pharmacological properties").

Lesions or conditions associated with a significant risk of major bleeding. These may include current or recent gastrointestinal ulceration, presence of malignant neoplasms with high bleeding risk, recent trauma to the brain or spinal cord, recent surgery on the brain or spinal cord or ophthalmological procedures, recent intracranial hemorrhage, diagnosed or suspected esophageal varices, arteriovenous malformations, vascular aneurysms, or prominent intraspinal or intracranial vascular abnormalities.

Concomitant use of any other anticoagulants, such as unfractionated heparin (UFH), low-molecular-weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), or oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.), except in specific circumstances of switching anticoagulant therapy (see section "Dosage and administration"): administration of UFH at doses required to maintain patency of a central venous or arterial catheter, or administration of UFH during catheter ablation for atrial fibrillation (see sections "Special precautions" and "Interaction with other medicinal products and other forms of interaction").

Interaction with other medicinal products and other forms of interaction.

CYP3A4 and P-gp inhibitors.

Concomitant administration of apixaban and ketoconazole (400 mg once daily), a potent inhibitor of both CYP3A4 and P-gp, resulted in a two-fold increase in mean AUC and a 1.6-fold increase in mean Cmax of apixaban.

Apixaban is not recommended for patients receiving systemic treatment with potent dual inhibitors of CYP3A4 and P-gp, such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see section "Special precautions").

Active substances not considered potent inhibitors of CYP3A4 and P-gp (e.g., amiodarone, clarithromycin, diltiazem, fluconazole, naproxen, quinidine, verapamil) may less intensively increase apixaban plasma concentrations. Dose adjustment of apixaban is not required when used concomitantly with agents that are not strong inhibitors of CYP3A4 and/or P-gp. For example, diltiazem (360 mg once daily), considered a moderate CYP3A4 inhibitor and weak P-gp inhibitor, increased mean AUC and Cmax of apixaban by 1.4- and 1.3-fold, respectively. Naproxen (single 500 mg dose), an inhibitor of P-gp but not CYP3A4, increased mean AUC and Cmax of apixaban by 1.5- and 1.6-fold, respectively. Clarithromycin (500 mg twice daily), an inhibitor of both P-gp and a strong CYP3A4 inhibitor, increased mean AUC and Cmax of apixaban by 1.6- and 1.3-fold, respectively.

CYP3A4 and P-gp inducers

Concomitant administration of apixaban and rifampicin (a potent inducer of both CYP3A4 and P-gp) resulted in approximately 54% and 42% reduction in mean AUC and Cmax of apixaban, respectively. Concomitant use of apixaban with other potent inducers of CYP3A4 and P-gp (e.g., phenytoin, carbamazepine, phenobarbital, or St. John's wort) may also lead to reduced plasma concentrations of apixaban. Dose adjustment of apixaban is not required when used concomitantly with such agents.

However, for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation (NVAF) and for prevention of recurrent DVT and PE, apixaban should be used with caution in patients receiving concomitant treatment with potent inducers of CYP3A4 and P-gp.

Apixaban is not recommended for the treatment of DVT and PE in patients receiving concomitant systemic treatment with potent inducers of CYP3A4 and P-gp, as its efficacy may be compromised (see section "Special precautions").

Anticoagulants, antiplatelet agents, selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), and non-steroidal anti-inflammatory drugs (NSAIDs)

Due to increased bleeding risk, concomitant use of any other anticoagulants is contraindicated, except in specific circumstances of switching anticoagulant therapy, when unfractionated heparin is administered at doses required to maintain patency of a central venous or arterial catheter, or when unfractionated heparin is administered during catheter ablation for atrial fibrillation (see section "Contraindications").

An additive effect on anti-Xa activity was observed after co-administration of enoxaparin (single 40 mg dose) and apixaban (single 5 mg dose).

No significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was administered concomitantly with acetylsalicylic acid (325 mg once daily).

Concomitant administration of apixaban with clopidogrel (75 mg once daily), or with a combination of 75 mg clopidogrel and 162 mg acetylsalicylic acid once daily, or with prasugrel (initial dose 60 mg, maintenance dose 10 mg once daily) in Phase I studies did not result in a significant increase in modeled bleeding time or further inhibition of platelet aggregation compared to antiplatelet agents alone. Changes in coagulation parameters (PT, INR, and aPTT) were consistent with the effects of apixaban as monotherapy.

Naproxen (500 mg), an inhibitor of P-gp, increased mean AUC and Cmax of apixaban by 1.5- and 1.6-fold, respectively. Apixaban caused a corresponding increase in coagulation parameters. Concomitant administration of naproxen and apixaban did not alter the effect of naproxen on arachidonic acid-induced platelet aggregation and did not lead to clinically significant prolongation of bleeding time. Nevertheless, in some individuals, a more pronounced pharmacodynamic response to concomitant administration of antiplatelet agents and apixaban may occur. Apixaban should be used with caution in combination with SSRIs/SNRIs, NSAIDs, acetylsalicylic acid, and/or P2Y12 inhibitors, as these medicinal products generally increase the risk of bleeding (see section "Special precautions").

Limited experience exists with concomitant use of other antiplatelet agents (such as GPIIb/IIIa receptor antagonists, dipyridamole, dextran, or sulfinpyrazone) or thrombolytic agents. Since these agents increase bleeding risk, their concomitant use with apixaban is not recommended (see section "Special precautions").

Other concomitant medications

No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was administered concomitantly with atenolol or famotidine. Concomitant administration of 10 mg apixaban and 100 mg atenolol had no clinically relevant effect on apixaban pharmacokinetics. After repeated co-administration of both drugs, mean AUC and Cmax of apixaban were 15% and 18% lower, respectively, compared to monotherapy. Concomitant administration of 10 mg apixaban and 40 mg famotidine had no effect on AUC or Cmax of apixaban.

Effect of apixaban on other medicinal products

In vitro studies with apixaban showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, or CYP3A4 (IC50 > 45 µmol/L), and weak inhibition of CYP2C19 activity (IC50 > 20 µmol/L) at concentrations significantly higher than peak plasma concentrations in patients. Apixaban at concentrations up to 20 µmol/L does not induce the activity of CYP1A2, CYP2B6, or CYP3A4/5. Therefore, apixaban is not expected to alter the metabolic clearance of concomitant drugs metabolized by these enzymes. Apixaban does not significantly inhibit P-gp activity.

As described below, in studies involving healthy volunteers, apixaban did not cause significant changes in the pharmacokinetics of digoxin, naproxen, or atenolol.

Digoxin

Concomitant administration of apixaban (20 mg once daily) and digoxin (0.25 mg once daily), a P-gp substrate, did not alter AUC or Cmax of digoxin. Thus, apixaban does not inhibit P-gp-mediated transport of substrates.

Naproxen

Concomitant administration of single doses of apixaban (10 mg) and the NSAID naproxen (500 mg) did not affect AUC or Cmax of naproxen.

Atenolol

Concomitant administration of single doses of apixaban (10 mg) and the beta-blocker atenolol (100 mg) did not affect the pharmacokinetics of atenolol.

Activated charcoal

Administration of activated charcoal reduces apixaban exposure levels (see section "Overdose").

Special precautions.

Bleeding risk

As with other anticoagulants, patients receiving apixaban require careful monitoring for signs of bleeding. The drug should be used with caution in conditions associated with an increased risk of bleeding. In the event of severe bleeding, apixaban should be discontinued (see sections "Adverse reactions" and "Overdose").

Although apixaban therapy does not require routine monitoring of drug exposure levels, in exceptional circumstances, when information on apixaban exposure levels may assist in making a clinical decision (e.g., in cases of overdose or emergency surgery), quantitative measurement of factor Xa inhibition activity may be used (see "Pharmacodynamics").

A specific antidote is available for neutralizing the activity of factor Xa inhibitors.

Interactions with other medicinal products affecting blood coagulation

Due to increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section "Contraindications").

Concomitant use of apixaban with antiplatelet agents increases the risk of bleeding (see section "Interaction with other medicinal products and other types of interactions").

Caution should be exercised if patients are concurrently receiving SSRIs or SNRIs, or NSAIDs, including acetylsalicylic acid.

Concomitant use of other platelet aggregation inhibitors with apixaban after surgical procedures is not recommended (see section "Interaction with other medicinal products and other types of interactions").

For patients with atrial fibrillation and conditions requiring mono- or dual antiplatelet therapy, the potential benefits and risks should be carefully weighed before combining such therapy with ELIQUIS.

In a clinical trial involving patients with atrial fibrillation, concomitant use of acetylsalicylic acid increased the risk of major bleeding associated with apixaban treatment from 1.8% per year to 3.4% per year, and the risk associated with warfarin from 2.7% per year to 4.6% per year. Concomitant dual antiplatelet therapy was limited in this clinical trial (2.1%) (see "Pharmacodynamics").

A clinical trial included patients with atrial fibrillation and/or those who underwent PCI with a planned treatment period with a P2Y12 inhibitor, with or without ASA, and an oral anticoagulant (apixaban or vitamin K antagonist (VKA)) for 6 months. Concomitant use of ASA in patients receiving apixaban increased the risk of major or non-major clinically relevant bleeding according to International Society on Thrombosis and Haemostasis (ISTH) criteria from 16.4% to 33.1% per year (see "Pharmacodynamics").

In a clinical trial involving high-risk patients after acute coronary syndrome without atrial fibrillation, who had multiple concomitant cardiovascular and non-cardiovascular conditions and were receiving acetylsalicylic acid or a combination of acetylsalicylic acid and clopidogrel, apixaban use was associated with a significant increase in the risk of major bleeding according to ISTH classification—5.13% per year compared to 2.04% per year in the placebo group.

Use of thrombolytic agents for the treatment of acute ischemic stroke

Experience with thrombolytic agents for the treatment of acute ischemic stroke in patients taking apixaban is extremely limited (see section "Interaction with other medicinal products and other types of interactions").

Patients with prosthetic heart valves

The safety and efficacy of apixaban have not been studied in patients with prosthetic heart valves, with or without atrial fibrillation. Therefore, apixaban is not recommended in this case.

Patients with antiphospholipid syndrome

Direct oral anticoagulants, including apixaban, are not recommended for patients with a history of thrombosis diagnosed with antiphospholipid syndrome. In particular, in patients positive for all three markers (lupus anticoagulant, anti-cardiolipin antibodies, and anti-beta-2-glycoprotein I antibodies), treatment with direct oral anticoagulants may be associated with an increased rate of recurrent thrombotic events compared to vitamin K antagonist therapy.

Surgical procedures and invasive procedures

Apixaban therapy should be discontinued at least 48 hours before elective surgery or invasive procedures with moderate or high bleeding risk. This applies to procedures where clinically significant bleeding cannot be ruled out and to interventions where the bleeding risk is unacceptable.

Apixaban therapy should be discontinued at least 24 hours before elective surgery or invasive procedures with low bleeding risk. This applies to procedures where any potential bleeding is expected to be minor in volume, non-critical to the site, or easily controllable.

If surgery or an invasive procedure cannot be postponed, appropriate precautionary measures should be taken, considering the increased bleeding risk. The risk of bleeding and the urgency of the procedure should be carefully weighed.

Apixaban therapy should be resumed as soon as possible after surgery or an invasive procedure, provided the clinical situation allows and adequate hemostatic measures have been taken (for cardioversion, see section "Dosage and administration").

Patients undergoing catheter ablation for the treatment of atrial fibrillation do not need to interrupt apixaban therapy (see sections "Dosage and administration", "Contraindications", and "Interaction with other medicinal products and other types of interactions").

Temporary discontinuation of treatment

Discontinuation of anticoagulant therapy (including apixaban) due to active bleeding, planned surgery, or invasive procedures increases the risk of thrombosis in patients. Treatment interruptions should be avoided, and if apixaban therapy must be temporarily discontinued (for any reason), the drug should be resumed as soon as possible.

Patients with PE and unstable hemodynamics, or patients requiring thrombolysis or pulmonary embolectomy

Apixaban is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism and unstable hemodynamics or those who may undergo thrombolysis or pulmonary embolectomy, as the safety and efficacy of apixaban in these clinical situations have not been established.

Patients with active cancer

Patients with active cancer may have a high risk of both venous thromboembolism and bleeding. When considering apixaban for the treatment of DVT or PE in cancer patients, the benefit-risk ratio should be carefully assessed (see section "Contraindications").

Patients with renal impairment

Some clinical data suggest that apixaban plasma concentrations are increased in patients with severe renal impairment (creatinine clearance 15–29 mL/min), which may increase the risk of bleeding. For the treatment of DVT, treatment of PE, and prevention of recurrent DVT and PE (VTEt), apixaban should be used with caution in patients with severe renal impairment (creatinine clearance 15–29 mL/min) (see "Pharmacokinetics" and section "Dosage and administration").

For stroke and systemic embolism prevention in patients with NVAF who have severe renal impairment (creatinine clearance 15–29 mL/min) or serum creatinine ≥ 1.5 mg/dL (133 µmol/L) in combination with age ≥ 80 years or body weight ≤ 60 kg, a lower dose of apixaban 2.5 mg twice daily should be used (see section "Dosage").

There is no clinical experience with apixaban in patients with creatinine clearance < 15 mL/min or in patients on dialysis; therefore, apixaban is not recommended for use in these patient populations (see "Pharmacokinetics" and section "Dosage and administration").

Geriatric patients

The risk of bleeding may increase with age (see "Pharmacokinetics").

Apixaban in combination with acetylsalicylic acid should also be used with caution in elderly patients due to an increased risk of bleeding.

Body weight

Low body weight (< 60 kg) increases the risk of bleeding (see "Pharmacokinetics").

Patients with hepatic impairment

Apixaban is contraindicated in patients with liver disease associated with coagulopathy and clinically relevant bleeding risk (see section "Contraindications").

The drug is not recommended for use in patients with severe hepatic impairment (see "Pharmacokinetics").

The drug should be used with caution in patients with mild or moderate hepatic impairment (Child-Pugh class A or B) (see "Pharmacokinetics" and section "Dosage and administration").

Patients with elevated liver enzymes alanine aminotransferase/aspartate aminotransferase (ALT/AST) > 2 times the upper limit of normal (ULN) or total bilirubin ≥ 1.5 ULN were excluded from clinical trials. Therefore, apixaban should be used with caution in this patient population (see "Pharmacokinetics"). Liver function tests should be performed before initiating apixaban therapy.

Interactions with inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp)

Apixaban should not be prescribed to patients receiving systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, and posaconazole) or HIV protease inhibitors (e.g., ritonavir). These drugs may double apixaban exposure (see section "Interaction with other medicinal products and other types of interactions") or even more in the presence of additional factors increasing apixaban exposure (such as severe renal impairment).

Interaction with CYP3A4 and P-gp inducers

Concomitant use of apixaban with strong inducers of CYP3A4 and P-gp (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John's wort preparations) may reduce apixaban exposure by approximately 50%. In a clinical trial involving patients with atrial fibrillation, concomitant use of apixaban with strong CYP3A4 and P-gp inducers reduced anticoagulant efficacy and increased bleeding risk compared to apixaban monotherapy.

For patients receiving concomitant treatment with strong CYP3A4 and P-gp inducers, the following recommendations apply (see section "Interaction with other medicinal products and other types of interactions"):

• apixaban should be used with caution for stroke and systemic embolism prevention in patients with NVAF and for prevention of recurrent DVT and PE;
• apixaban should not be used for the treatment of DVT and PE, as its efficacy may be compromised.

Laboratory parameters

As expected, the mechanism of action of apixaban affects blood coagulation parameters (e.g., prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT)). Changes observed in these test results during therapeutic dosing are minor and highly variable (see "Pharmacodynamics").

Information on excipients

ELIQUIS contains lactose.

This medicine should not be used by patients with rare hereditary conditions associated with galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption syndrome.

ELIQUIS contains sodium.

This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, i.e., essentially "sodium-free".

Use during pregnancy or breastfeeding.

Use during pregnancy

There are no data on the use of apixaban in pregnant women. Animal studies did not reveal direct or indirect harmful effects on reproductive toxicity (see "Preclinical safety data"). As a precautionary measure, apixaban use during pregnancy is not recommended.

Use during breastfeeding

It is currently unknown whether apixaban or its metabolites pass into human breast milk. Animal studies indicate that apixaban is excreted in milk (see "Preclinical safety data"). Risk to the breastfed infant cannot be excluded.

A decision should be made whether to discontinue breastfeeding or to discontinue/avoid apixaban therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

Fertility

Animal studies with direct administration of apixaban did not reveal any effect of the drug on fertility (see "Preclinical safety data").

Ability to affect reaction speed when driving or operating machinery.

ELIQUIS has no effect or a negligible effect on the ability to drive or operate machinery.

Dosage and Administration

Dosage

Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation

The recommended dose of ELIQUIS is 5 mg orally twice daily.

Dose reduction

For patients with non-valvular atrial fibrillation and at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL (133 µmol/L), the recommended dose of ELIQUIS is 2.5 mg orally twice daily.

Treatment should be continued long-term.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prevention of DVT and PE recurrence (VTE)

The recommended dose of ELIQUIS for the treatment of DVT and PE is 10 mg orally twice daily for the first 7 days, followed by 5 mg orally twice daily. According to current medical guidelines, the duration of treatment (at least 3 months) should take into account transient risk factors (e.g., recent surgery, trauma, immobilization).

The recommended dose of ELIQUIS for the prevention of recurrent DVT and PE is 2.5 mg orally twice daily. If a patient requires prevention of recurrent DVT and PE, the 2.5 mg twice-daily dose should be initiated after completing a 6-month course of ELIQUIS 5 mg twice daily or a course of treatment with another anticoagulant, as specified in Table 12 (see also "Pharmacodynamics").

Table 12
Dosing recommendations (VTE)

The duration of the overall treatment course should be determined individually after careful assessment of the benefits of treatment and the risk of bleeding (see section "Special precautions").

Missed dose

If a dose has been missed, the patient should take ELIQUIS immediately and continue treatment in the usual manner, twice daily.

Switching between medicinal products

Switching from parenteral administration of anticoagulants to treatment with ELIQUIS (and vice versa) can be performed at the time of the next scheduled dose (see section "Interaction with other medicinal products and other forms of interaction"). These medicinal products should not be used simultaneously.

Transition from vitamin K antagonist therapy to ELIQUIS

When switching patients from vitamin K antagonist therapy to ELIQUIS, discontinue warfarin or another vitamin K antagonist and initiate ELIQUIS when the international normalized ratio (INR) is < 2.0.

Transition from ELIQUIS to vitamin K antagonist therapy

When switching patients from ELIQUIS to vitamin K antagonist therapy, continue ELIQUIS for at least 2 days after initiation of vitamin K antagonist therapy. After two days of concomitant administration of apixaban and vitamin K antagonist, determine the international normalized ratio (INR) before taking the next dose of ELIQUIS. Combined treatment with ELIQUIS and vitamin K antagonist should continue until the INR reaches levels ≥ 2.0.

Elderly patients

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prevention of DVT and PE recurrence in adults: no dose adjustment is required (see "Pharmacokinetics" and section "Special precautions").

Non-valvular atrial fibrillation: dose adjustment is not required, except for cases specified above (see "Dose reduction").

Renal impairment

The following recommendations apply to patients with mild or moderate renal impairment:

• for treatment of DVT, treatment of PE, and prevention of DVT or PE recurrence (VTEt), no dose adjustment is required (see "Pharmacokinetics");
• for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and serum creatinine level ≥ 1.5 mg/dL (133 µmol/L) in combination with such factors as age ≥ 80 years or body weight ≤ 60 kg, a lower dose of apixaban should be used as described above. In the absence of other criteria for dose reduction (age, body weight), dose adjustment is not required (see "Pharmacokinetics").

For patients with severe renal impairment (creatinine clearance 15–29 mL/min), the following recommendations apply (see "Pharmacokinetics" and section "Special precautions"):

• for treatment of DVT, treatment of PE, and prevention of DVT or PE recurrence (VTEt), apixaban should be used with caution;
• for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), a lower dose of apixaban 2.5 mg twice daily should be used.

There is no clinical experience with apixaban in patients with creatinine clearance < 15 mL/min or in patients on dialysis; therefore, apixaban is not recommended for use in these patient populations (see "Pharmacokinetics" and section "Special precautions").

Hepatic impairment

ELIQUIS is contraindicated in patients with liver disease associated with coagulopathy and clinically relevant bleeding risk (see section "Contraindications").

The medicinal product is not recommended for use in patients with severe hepatic impairment (see "Pharmacokinetics" and section "Special precautions").

ELIQUIS should be used with caution in patients with mild or moderate hepatic impairment (Child-Pugh class A or B); such patients do not require dose adjustment (see "Pharmacokinetics" and section "Special precautions").

Patients with elevated liver enzymes (ALT/AST > 2 ULN) or total bilirubin ≥ 1.5 ULN were excluded from clinical trials. Therefore, ELIQUIS should be used with caution in this patient group (see "Pharmacokinetics" and section "Special precautions"). Liver function tests should be performed before initiating treatment with ELIQUIS.

Body weight

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults: no dose adjustment is required (see "Pharmacokinetics" and section "Special precautions").

Non-valvular atrial fibrillation: dose adjustment is not required, except for cases specified above (see "Dose reduction").

Gender

No dose adjustment is required (see "Pharmacokinetics").

Patients undergoing catheter ablation

Patients may continue receiving apixaban during catheter ablation (see sections "Contraindications", "Special precautions", and "Interaction with other medicinal products and other forms of interaction").

Patients undergoing cardioversion

Patients with NVAF who require cardioversion may initiate or continue apixaban.

In patients who have not previously received anticoagulants, the presence of left atrial thrombus should be excluded using imaging techniques (e.g., transesophageal echocardiography or computed tomography) prior to cardioversion, in accordance with established medical guidelines.

Patients initiating apixaban therapy should receive 5 mg twice daily for at least 2.5 days (5 doses) prior to cardioversion to ensure adequate anticoagulation (see "Pharmacodynamics"). If the patient meets criteria for dose reduction (see "Dose reduction" and "Renal impairment"), the dose should be reduced to 2.5 mg apixaban twice daily for at least 2.5 days (5 doses).

If cardioversion is required, a loading dose of 10 mg should be administered before the fifth dose of apixaban, followed by 5 mg twice daily. The dosing regimen should be reduced to a loading dose of 5 mg, followed by 2.5 mg twice daily, if the patient meets criteria for dose reduction (see "Dose reduction" and "Renal impairment"). The loading dose should be taken at least 2 hours before cardioversion (see "Pharmacodynamics").

For all patients undergoing cardioversion, it should be confirmed that the patient has been taking apixaban as prescribed. Decisions regarding initiation and duration of treatment should be made in accordance with established guidelines for anticoagulant use in patients undergoing cardioversion.

Patients with non-valvular atrial fibrillation (NVAF) and/or acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI)

There is limited experience with the use of apixaban at the recommended dose in patients with NVAF in combination with antiplatelet agents, and in patients with ACS and/or those undergoing PCI after achieving hemostasis (see "Pharmacodynamics" and section "Special precautions").

Method of administration

The medicinal product is administered orally.

ELIQUIS should be taken with water, with or without food.

For patients unable to swallow whole tablets, ELIQUIS tablets may be crushed and suspended in water or 5% aqueous glucose solution or apple juice, or mixed with apple puree and administered orally immediately (see "Pharmacokinetics"). Alternatively, ELIQUIS tablets may be crushed and suspended in 60 mL of water or 5% aqueous glucose solution and administered immediately via a nasogastric tube (see "Pharmacokinetics"). ELIQUIS tablets, after crushing, are stable in water, 5% aqueous glucose solution, apple juice, or apple puree for up to 4 hours.

Children

The efficacy and safety of ELIQUIS in children (under 18 years of age) have not been established.

Current data on thromboembolism prevention are described in the "Pharmacokinetics" section, but dosing recommendations cannot be made.

Overdose

Overdose of apixaban may lead to an increased risk of bleeding. In the event of hemorrhagic complications, treatment should be discontinued and the source of bleeding investigated. Appropriate management should be considered, such as surgical hemostasis, transfusion of fresh frozen plasma, or administration of a factor Xa inhibitor reversal agent.

In controlled clinical studies, oral administration of apixaban to healthy volunteers at doses up to 50 mg daily for 3–7 days (25 mg twice daily for 7 days or 50 mg once daily for 3 days) did not result in clinically significant adverse reactions.

In healthy volunteers, administration of activated charcoal 2 and 6 hours after ingestion of 20 mg apixaban resulted in a reduction of mean apixaban AUC by 50% and 27%, respectively, and had no effect on Cmax. Administration of activated charcoal 2 or 6 hours after apixaban intake reduced the elimination half-life of apixaban, which was 13.4 hours under monotherapy, to 5.3 and 4.9 hours, respectively. Thus, administration of activated charcoal may be beneficial in the treatment of apixaban overdose or accidental ingestion.

For reversal of anticoagulation in cases of life-threatening bleeding or uncontrolled bleeding, a specific reversal agent for factor Xa inhibitors is available (see section "Special precautions"). Administration of prothrombin complex concentrate (PCC) or recombinant factor VIIa may also be considered. Reversal of the pharmacodynamic effects of apixaban, as confirmed by changes in thrombin generation assays, was evident at the end of infusion and returned to baseline within 4 hours after the start of a 30-minute PCC infusion in healthy volunteers. However, there is no clinical experience with the use of four-factor prothrombin complex concentrate to control bleeding in individuals receiving apixaban. Experience with recombinant factor VIIa for treatment of individuals receiving apixaban is currently lacking. Repeated administration of recombinant factor VIIa and dose titration based on bleeding normalization should be considered.

In cases of significant bleeding, consultation with a hematologist should be considered.

After a single 5 mg oral dose of apixaban, hemodialysis reduced apixaban AUC by 14% in patients with end-stage renal disease. Therefore, hemodialysis is unlikely to be an effective method for treating apixaban overdose.

Adverse reactions

The safety of apixaban was evaluated in four Phase III clinical trials involving over 15,000 patients: over 11,000 patients in atrial fibrillation (AF) studies and over 4,000 patients in venous thromboembolism treatment (VTEt) studies. The mean overall duration of exposure was 1.7 years and 221 days, respectively (see "Pharmacodynamics").

Common adverse reactions included bleeding, bruising, epistaxis, and hematoma (the adverse event profile and frequencies, classified by indication, are presented in Table 13).

In the AF studies, the overall incidence of bleeding-related adverse reactions in the apixaban group was 24.3% in the apixaban versus warfarin comparison study and 9.6% in the apixaban versus acetylsalicylic acid comparison study. In the apixaban versus warfarin comparison study, the rate of major gastrointestinal bleeding according to ISTH (International Society on Thrombosis and Haemostasis) classification (including upper gastrointestinal tract, lower gastrointestinal tract, and rectal bleeding) in patients receiving apixaban was 0.76%/year. The rate of major intraocular bleeding according to ISTH classification in patients receiving apixaban was 0.18%/year.

In the VTEt studies, the overall incidence of bleeding-related adverse reactions in the apixaban group was 15.6% in the apixaban versus enoxaparin/warfarin comparison study and 13.3% in the apixaban versus placebo comparison study (see "Pharmacodynamics").

Table 13 lists the adverse reactions observed during administration of the drug, organized by system organ class and frequency: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), and not known (cannot be estimated from available data), for AF and VTEt, respectively.

Table 13

Table of adverse reactions

* In the CV185057 study (long-term VTE prophylaxis), cases of generalized pruritus were not observed.

† The term "Intracranial hemorrhage" includes all intracerebral or intraspinal hemorrhages (e.g., hemorrhagic stroke or putaminal hemorrhage, cerebellar, intraventricular, or subdural hemorrhages).

The use of apixaban may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may lead to post-hemorrhagic anemia. Signs, symptoms, and their severity will vary depending on the location and extent or magnitude of bleeding (see "Pharmacodynamics" and section "Special precautions").

Reporting suspected adverse reactions

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continuous monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals, pharmacists, as well as patients or their legal representatives, should report all suspected adverse reactions and lack of efficacy through the Automated Pharmacovigilance Information System at the following link: https://aisf.dec.gov.ua.

Shelf life.

4 years.

Storage conditions.

No special storage conditions required.

Keep the medicinal product out of the reach of children.

Packaging.

Film-coated tablets, 5 mg, 10 tablets per blister, 6 blisters per cardboard box.

Prescription status.

Prescription only.

Manufacturer.

Belupo, pharmaceuticals and cosmetics, Inc. / Belupo, lijekovi i kozmetika, d.d.

Manufacturer's address and location of its operations.

Ulica Danica 5, 48 000 Koprivnica, Croatia / Ulica Danica 5, 48 000 Koprivnica, Croatia.